As the understanding of oncology progresses, it has become clear that the fight against cancer requires innovation from many angles. With a multifaceted approach to research and development, we are investigating a broad range of antitumor modalities, including individualized neoantigen-specific therapy, innovative bispecific antibodies, and novel antibody drug conjugates.
In the continued pursuit of truly personalized healthcare, we aim to improve specificity across all development platforms, to further identify the right approach for the right patient, and to transform the way cancer is treated in areas of unmet clinical need.
See the science behind Genentech's continued development of antibody drug conjugates (ADCs) and the potential of delivering highly potent cytotoxins directly to malignant B cells and other tumors.1,2
Learn more about the potential of inducing antitumor immune responses through our investigational Individualized NeoAntigen Specific Immunotherapy (iNeST).3
Read more about our diverse approaches to transforming the innate ability of antibodies into potential therapeutic agents against cancer.4
Read more about our continued research in targeting intracellular tumor mechanisms to interrupt pathway dysregulation.5,6
Discover our unique bispecific antibody design technologies and the innovative method of harnessing the immune system to fight cancer through the simultaneous binding of T cells and tumor-cell antigens.7,8
Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089. PMID: 26182432
Polson AG, Yu S-F, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616-623. PMID: 17374736
Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222-226. PMID: 28678784
Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist. 2007;12:1084-1095. PMID: 17914078
Hanahan D, Weinberg D. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. PMID: 21376230
Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381-405. PMID: 28431241
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.